3-[2-(Pyridin-4-yl)-1,3-thiazol-4-yl]pyridine | 863111-83-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-[2-(Pyridin-4-yl)-1,3-thiazol-4-yl]pyridine
• 英文别名: 4-pyridin-3-yl-2-pyridin-4-yl-1,3-thiazole
• CAS: 863111-83-5
• 化学式: C₁₃H₉N₃S
• 分子量: 239.301
• InChiKey: RJSRAVGLLFFTHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  硫代异烟酰胺 、 3-(2-溴乙酰基)吡啶氢溴酸盐 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-[2-(Pyridin-4-yl)-1,3-thiazol-4-yl]pyridine
  参考文献：
  名称：

  Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol

  摘要：

  Aromatase is an established target not only for breast cancer chemotherapy, but also for breast cancer chemoprevention. The moderate and non-selective aromatase inhibitory activity of resveratrol (1) was improved about 100-fold by replacement of the ethylenic bridge with a thiadiazole and the phenyl rings with pyridines (e.g., compound 3). The aromatase inhibitory activity was enhanced over 6000-fold by using a 1,3-thiazole as the central ring and modifying the substituents on the 'A' ring to target the Met374 residue of aromatase. On the other hand, targeting the hydroxyl group of Thr310 by a hydrogen-bond acceptor on the 'B' ring did not improve the aromatase inhibitory activity. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.01.047

文献信息

• [EN] HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAIN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS CIBLANT LE DOMAINE DE LIAISON À L'ADN (DBD) DU RÉCEPTEUR DES ANDROGÈNES HUMAIN SERVANT D'AGENTS THÉRAPEUTIQUES ET PROCÉDÉS POUR LEUR UTILISATION
  申请人：UNIV BRITISH COLUMBIA

  公开号：WO2015120543A1

  公开（公告）日：2015-08-20

  A compound having the structure of Formula I, wherein A is a substituted or unsubstituted aryl or heteroaryl group, D is a substituted or unsubstituted 5- or 6-mcmbcrcd heteroaryl or heterocyclyl group and E is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl or heterocyclyl group. The compounds are used for the treatment of androgen modulated indications including cancer (prostate, breast, ovarian, endometrial or blader cancer), hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty and age related macular degeneration. The use of the compounds for the manufacture of a medicament for modulating AR activity, a method of treatment using such compounds and a pharmaceutical composition and a commercial package comprising said compounds arc also described.

  一种具有公式I结构的化合物，其中A是取代或未取代的芳基或杂芳基基团，D是取代或未取代的5-或6-成员杂芳基或杂环基基团，E是取代或未取代的芳基，杂芳基，环烷基或杂环基基团。这些化合物用于治疗雄激素调节的症状，包括癌症（前列腺，乳腺，卵巢，子宫内膜或膀胱癌），脱发，痤疮，多毛症，卵巢囊肿，多囊卵巢综合症，早熟和年龄相关性黄斑变性。还描述了使用这些化合物制造调节雄激素受体活性的药物、使用这些化合物的治疗方法、以及包含这些化合物的制药组合物和商业包装。
• Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use
  申请人：The University of British Columbia

  公开号：US10011573B2

  公开（公告）日：2018-07-03

  A compound having the structure of Formula I, wherein A is a substituted or unsubstituted aryl or heteroaryl group, D is a substituted or unsubstituted 5- or 6-membered heteroaryl or heterocyclyl group and E is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl or heterocyclyl group. The compounds are used for the treatment of androgen modulated indications including cancer (prostate, breast, ovarian, endometrial or bladder cancer), hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty and age related macular degeneration. The use of the compounds for the manufacture of a medicament for modulating AR activity, a method of treatment using such compounds and a pharmaceutical composition and a commercial package comprising said compounds are also described.

  具有式 I 结构的化合物，其中 A 是取代或未取代的芳基或杂芳基，D 是取代或未取代的 5 或 6 元杂芳基或杂环基，E 是取代或未取代的芳基、杂芳基、环烷基或杂环基。这些化合物可用于治疗雄激素调节适应症，包括癌症（前列腺癌、乳腺癌、卵巢癌、子宫内膜癌或膀胱癌）、脱发、痤疮、多毛症、卵巢囊肿、多囊卵巢病、性早熟和老年性黄斑变性。此外，还描述了这些化合物在制造调节 AR 活性的药物中的用途、使用这些化合物的治疗方法以及包含上述化合物的药物组合物和商业包装。
• HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE
  申请人：The University of British Columbia

  公开号：US20170183319A1

  公开（公告）日：2017-06-29

  A compound having the structure of Formula I, wherein A is a substituted or unsubstituted aryl or heteroaryl group, D is a substituted or unsubstituted 5- or 6-membered heteroaryl or heterocyclyl group and E is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl or heterocyclyl group. The compounds are used for the treatment of androgen modulated indications including cancer (prostate, breast, ovarian, endometrial or blader cancer), hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty and age related macular degeneration. The use of the compounds for the manufacture of a medicament for modulating AR activity, a method of treatment using such compounds and a pharmaceutical composition and a commercial package comprising said compounds arc also described.
• Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol
  作者：Abdelrahman S. Mayhoub、Laura Marler、Tamara P. Kondratyuk、Eun-Jung Park、John M. Pezzuto、Mark Cushman

  DOI：10.1016/j.bmc.2012.01.047

  日期：2012.4

  Aromatase is an established target not only for breast cancer chemotherapy, but also for breast cancer chemoprevention. The moderate and non-selective aromatase inhibitory activity of resveratrol (1) was improved about 100-fold by replacement of the ethylenic bridge with a thiadiazole and the phenyl rings with pyridines (e.g., compound 3). The aromatase inhibitory activity was enhanced over 6000-fold by using a 1,3-thiazole as the central ring and modifying the substituents on the 'A' ring to target the Met374 residue of aromatase. On the other hand, targeting the hydroxyl group of Thr310 by a hydrogen-bond acceptor on the 'B' ring did not improve the aromatase inhibitory activity. (C) 2012 Elsevier Ltd. All rights reserved.